In this regard, while in sarcoma cells opposite effects on cell proliferation have been ascribed to the catalytic domain of LOX and LOX-PP29, in prostate cancer, active LOX seems to exhibit a dual behavior acting either as a tumor-suppressor or as a tumor-promoter probably depending on the stage of disease30. The gene discussed is LOX; the disease is prostate cancer.